Tradestie Institutional Equity Comparison Engine

CRIS vs BGMSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRIS Overall Edge

CRIS Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Curis Inc (CRIS) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, CRIS trades at N/M Forward P/E with -833.4% operating margin (-66.0% YoY revenue) versus BGMSP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CRIS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CRIS
CRIS N/M vs BGMSP N/M Fwd P/E
Growth & Margin Winner CRIS
Op Margin -833.4% vs N/A ยท YoY -66.0% vs N/A
Momentum & Technical Winner CRIS
1Y -61.0% vs -72.6% ยท 52W Pos 4% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CRIS NASDAQ
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap $3.8M
1M Return +8.14%
1Y Return -61.04%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 15.0 Fund 41.0 Flow 50.0 Mom 64.0
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
1M Return -60.98%
1Y Return -72.57%
Forward P/E N/M
Unified AI Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRIS -61.04% BGMSP -72.57% Spread: +30.39 pp (CRIS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRIS TTM Op. Margin: -833.4% BGMSP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRIS vs BGMSP. Trailing 12-month operating profitability (CRIS -833.4% vs BGMSP N/A) and valuation multiples (CRIS N/M vs BGMSP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRIS (7) vs BGMSP (2)
Institutional Metric CRIS BGMSP Criterion Row Winner
Market Capitalization Scale $3.8M N/A Larger Scale CRIS
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple CRIS
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -66.0% N/A Higher Growth CRIS
Operating Margin (TTM) Profitability -833.4% N/A Higher Margin CRIS
Net Profit Margin Profitability 0.0% N/A Higher Margin CRIS
Return on Equity (ROE) Capital Efficiency -693.9% N/A Higher ROE CRIS
52-Week Range Position Momentum 4% ($0โ€“$7) 0% ($1โ€“$14) Stronger Trend CRIS
Beta / 30D Volatility Risk Regime 11.40ฮฒ ยท 269% Vol 0.59ฮฒ ยท 201% Vol Lower Realized Risk BGMSP
Unified Institutional Score Composite Signal 38.7 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite BGMSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRIS vs BGMSP Buy Guide
CRIS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CRIS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BGMSP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGMSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRIS nor BGMSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.